Fluvoxamine for the treatment of COVID-19
- PMID: 35180410
- PMCID: PMC8846602
- DOI: 10.1016/S2214-109X(22)00003-1
Fluvoxamine for the treatment of COVID-19
Conflict of interest statement
We declare no competing interests.
Comment in
-
Fluvoxamine for the treatment of COVID-19.Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1. Lancet Glob Health. 2022. PMID: 35180411 Free PMC article. No abstract available.
Comment on
-
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Lancet Glob Health. 2022. PMID: 34717820 Free PMC article. Clinical Trial.
-
Fluvoxamine for the treatment of COVID-19.Lancet Glob Health. 2022 Mar;10(3):e329. doi: 10.1016/S2214-109X(21)00590-8. Lancet Glob Health. 2022. PMID: 35180409 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources